L Foretova

Summary

Affiliation: Masaryk Memorial Cancer Institute
Country: Czech Republic

Publications

  1. pmc Multiple Myeloma and lifetime occupation: results from the EPILYMPH study
    Carla Perrotta
    Medicina Familiar y Comunitaria, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
    J Occup Med Toxicol 7:25. 2012
  2. ncbi [Li-Fraumeni syndrome - a proposal of complex prevention care for carriers of TP53 mutation with total-body MRI]
    L Foretova
    Oddelení epidemiologie a genetiky nádorů, Masarykův Onkologický ústav, Brno
    Klin Onkol 25:S49-54. 2012
  3. pmc High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic
    Petra Vasickova
    Masaryk Memorial Cancer Institute, Brno, Czech Republic
    BMC Med Genet 8:32. 2007
  4. pmc Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer
    Eva Machackova
    Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
    BMC Cancer 8:140. 2008
  5. ncbi BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic
    Lenka Foretova
    Department of Cancer Epidemiology and Genetics, and Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53 Czech Republic
    Hum Mutat 23:397-8. 2004
  6. ncbi [Limitations of genetic testing in oncology]
    L Foretova
    Oddelení epidemiologie a genetiky nádorů, Masarykův onkologický ú, Brno
    Klin Onkol 22:S65-8. 2009
  7. pmc Genetic and preventive services for hereditary breast and ovarian cancer in the czech republic
    Lenka Foretova
    Masaryk Memorial Cancer Institute Brno
    Hered Cancer Clin Pract 4:3-6. 2006
  8. ncbi Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience
    L Foretova
    Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
    Klin Onkol 23:388-400. 2010
  9. ncbi [Diagnostics of breast cancer in high-risk women - our own experience]
    M Palacova
    klinika komplexní onkologické péce, Masarykův Onkologický ústav, Brno
    Klin Onkol 25:S96-8. 2012
  10. ncbi Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic
    E Machackova
    Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic
    Hum Mutat 18:545. 2001

Collaborators

Detail Information

Publications23

  1. pmc Multiple Myeloma and lifetime occupation: results from the EPILYMPH study
    Carla Perrotta
    Medicina Familiar y Comunitaria, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
    J Occup Med Toxicol 7:25. 2012
    ..abstract:..
  2. ncbi [Li-Fraumeni syndrome - a proposal of complex prevention care for carriers of TP53 mutation with total-body MRI]
    L Foretova
    Oddelení epidemiologie a genetiky nádorů, Masarykův Onkologický ústav, Brno
    Klin Onkol 25:S49-54. 2012
    ..Biochemical tests, ultrasound, MRI may improve survival of these high risk individuals and support the possibility of predictive testing in children...
  3. pmc High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic
    Petra Vasickova
    Masaryk Memorial Cancer Institute, Brno, Czech Republic
    BMC Med Genet 8:32. 2007
    ..The purpose of this study was to determine the type and frequency of large genomic rearrangements in the BRCA1 gene in hereditary breast and ovarian cancer cases in the Czech Republic...
  4. pmc Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer
    Eva Machackova
    Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
    BMC Cancer 8:140. 2008
    ..One thousand and ten unrelated high-risk probands with breast and/or ovarian cancer were analysed for the presence of a BRCA1 or BRCA2 gene mutation at the Masaryk Memorial Cancer Institute (Czech Republic) during 1999-2006...
  5. ncbi BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic
    Lenka Foretova
    Department of Cancer Epidemiology and Genetics, and Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 656 53 Czech Republic
    Hum Mutat 23:397-8. 2004
    ..2%) of 32 women with sporadic early-onset unilateral breast cancer. No mutation was detected in 5 cases of sporadic early-onset unilateral ovarian cancer...
  6. ncbi [Limitations of genetic testing in oncology]
    L Foretova
    Oddelení epidemiologie a genetiky nádorů, Masarykův onkologický ú, Brno
    Klin Onkol 22:S65-8. 2009
    ..In some variants it is not clear yet whether they are just insignificant polymorphisms or pathogenic mutations. The interpretation of test results in the context of the whole family history is important...
  7. pmc Genetic and preventive services for hereditary breast and ovarian cancer in the czech republic
    Lenka Foretova
    Masaryk Memorial Cancer Institute Brno
    Hered Cancer Clin Pract 4:3-6. 2006
    ..The quality of preventive care in different hospitals is currently being investigated...
  8. ncbi Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience
    L Foretova
    Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
    Klin Onkol 23:388-400. 2010
    ..However, in some patients the testing is not recommended and other family members are dying because of the late diagnosis of hereditary syndrome. Greater awareness of the importance of genetic testing in oncology is needed...
  9. ncbi [Diagnostics of breast cancer in high-risk women - our own experience]
    M Palacova
    klinika komplexní onkologické péce, Masarykův Onkologický ústav, Brno
    Klin Onkol 25:S96-8. 2012
    ..During the 11 years of clinical follow-up 32 breast cancers in 31 women were detected. High risk women are examined every 6 month by physical examination, breast ultrasound and MRI plus mammography yearly...
  10. ncbi Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic
    E Machackova
    Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic
    Hum Mutat 18:545. 2001
    ....
  11. ncbi [Male breast cancer--our experience]
    L Fiala
    Masarykův onkologický ústav Brno, Oddelení Chirurgické Onkologie
    Rozhl Chir 89:612-8. 2010
    ..2% of all cancers. The ratio of female to male breast cancer is approximately 100:1. In this study, we review our experience with diagnosis, surgical treatment, and overall management of patients with MBC...
  12. ncbi A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families
    E Machackova
    Cas Lek Cesk 139:635-7. 2000
    ..About 5-10% of breast and ovarian cancer can be of hereditary origin. Germline mutations in BRCA1 or BRCA2 and probably other yet unknown genes may cause predisposition to these cancers...
  13. ncbi Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2
    Kathleen Claes
    Center for Medical Genetics, Ghent University Hospital, Belgium
    Genes Chromosomes Cancer 37:314-20. 2003
    ..Furthermore, our study is important for a better understanding of splicing mechanisms and revealed new patterns of alternative splicing in BRCA1 and BRCA2...
  14. pmc AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study
    Fergus J Couch
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 16:1416-21. 2007
    ..In summary, the F31I polymorphism in AURKA is not associated with a modified risk of breast cancer in BRCA1 and BRCA2 carriers...
  15. ncbi Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer
    Tom Walsh
    Department of Medicine and Genome Sciences, University of Washington, Seattle, WA 98195 7720, USA
    JAMA 295:1379-88. 2006
    ..Furthermore, other breast cancer genes generally are not evaluated...
  16. ncbi The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic
    Zdenek Kleibl
    Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, U nemocnice 5, Prague, 12853, Czech Republic
    Breast Cancer Res Treat 90:165-7. 2005
    ..1100delC mutation varies among different populations. Based on our results, genotyping of CHEK2 c.1100delC mutation in clinical settings in the Czech Republic could not be recommended...
  17. ncbi Inherited predisposition of lung cancer: a hierarchical modeling approach to DNA repair and cell cycle control pathways
    Rayjean J Hung
    IARC, 150 cours Albert Thomas, F 69372 Lyon Cedex 08, France
    Cancer Epidemiol Biomarkers Prev 16:2736-44. 2007
    ..In particular, further investigation of OGG1, MGMT, and CHEK2 focusing on the genetic regions where the present markers are located or the haplotype blocks tightly linked with these markers might be warranted...
  18. ncbi A rare tumor and an ethical dilemma in a family with a germline TP53 mutation
    Kamila Prochazkova
    Department of Biology and Medical Genetics, Charles University 2nd Medical School and University Hospital Motol, Vuvalu 84, 15006 Prague 5, Czech Republic
    Cancer Genet Cytogenet 180:65-9. 2008
    ..The case illustrates ethical problems associated with early predisposition testing in LFS, and the lack of consensus on this issue in the literature...
  19. ncbi Epstein-Barr virus infection and risk of lymphoma: immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controls
    Silvia de Sanjose
    Servei d Epidemiologia and Registre del Cancer, IDIBELL, Institut Catala d Oncologia, Gran Via Km 2 7, 08907 L Hospitalet, Barcelona, Spain
    Int J Cancer 121:1806-12. 2007
    ..Ab_EBV is a useful tool to explore EBV imbalances preceding or paralleling possible EBV associated oncogenic events...
  20. ncbi Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes
    Federica Gemignani
    Genetics, Department of Biology, University of Pisa, Pisa, Italy
    Carcinogenesis 28:1287-93. 2007
    ..Finally, extensive EPHX1 metabolizers showed an increased risk as compared with the poor metabolizers...
  21. pmc Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph)
    Sophia S Wang
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Boulevard, Bethesda, MD 20892, USA
    Blood 109:3479-88. 2007
    ..0; 95% CI = 1.6-5.6). The pattern of NHL heritability appeared to be uniform across NHL subtypes, but risk patterns differed by specific hematopoietic malignancies and the sex of the relative, revealing critical clues to disease etiology...
  22. ncbi Influence of familial cancer history on lymphoid neoplasms risk validated in the large European case-control study epilymph
    Romain Casey
    Registre des Hémopathies Malignes de Côte d Or, EA INSERM InVs 4T0003C, faculté de médecine de Dijon, 7 Boulevard Jeanne d Arc, 21 000 Dijon, France
    Eur J Cancer 42:2570-6. 2006
    ..Our study suggests familial aggregation of CLL with a family history of haematological cancer and of HL with a family history of lymphoma. The transmission pattern suggests a dominant model of heredity...
  23. ncbi A Li-Fraumeni syndrome family with retained heterozygosity for a germline TP53 mutation in two tumors
    Marie Trkova
    Institute of Biology and Medical Genetics, Second Medical School, Charles University, Prague, Czech Republic
    Cancer Genet Cytogenet 145:60-4. 2003
    ..The product of the normal allele can potentially be inactivated by a variety of other mechanisms or, as suggested by the analysis, many of these tumors may even preserve the activity of the wild-type p53 protein...